Literature DB >> 8301549

Beta adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4.

N M Munoz1, A J Vita, S P Neeley, K McAllister, S M Spaethe, S R White, A R Leff.   

Abstract

The inhibitory effect of beta-2 adrenergic receptor stimulation on leukotriene C4 (LTC4) secretion and eosinophil peroxidase (EPO) release caused by exogenous activation with 10(-8) to 10(-6) M formyl-met-leu-phe (fMLP) + 5 micrograms/ml of cytochalasin B (Cyto B) in purified human peripheral blood eosinophils was studied. Cells from normal subjects were isolated by negative immunoselection and remained > or = 98% viable as determined by trypan blue exclusion. Duplicate aliquots of eosinophils (10(5) cells/intervention) were activated with 1) fMLP + Cyto B alone, 2) fMLP + Cyto B after pretreatment with 10(-8) M albuterol, 3) 10(-8) M albuterol + fMLP + Cyto B after pretreatment with 10(-8) M propranolol or 4) vehicle control. After incubation, the supernatants were tested for concentration of LTC4 and EPO. Concentration-related release of EPO was demonstrated for 10(-8) M fMLP + 5 micrograms/ml of Cyto B to 10(-6) M fMLP + 5 micrograms/ml of Cyto B, and the greatest concentration of fMLP was used in all subsequent studies. FMLP + Cyto B caused substantial LTC4 secretion in eosinophils (300 +/- 83.0 pg/ml) as compared to sham-activated eosinophils (3.3 +/- 1.9 pg/ml; P < .02). Similarly, maximum EPO release increased from 277 +/- 17.8 to 3956 +/- 1230 ng/10(6) cells (P < .02) after activation with fMLP + Cyto B. Treatment with albuterol decreased markedly both LTC4 secretion to 144 +/- 54.0 pg/ml (P < .05 vs. fMLP + Cyto B-activated eosinophils) and EPO release to 1993 +/- 368 ng/10(6) cells (P < .05 vs. fMLP + Cyto B-activated eosinophils).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301549

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 2.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

3.  Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.

Authors:  J Cortijo; V Villagrasa; R Pons; L Berto; M Martí-Cabrera; M Martinez-Losa; T Domenech; J Beleta; E J Morcillo
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  R2D(2) for C(4)Eo: an 'alliance' of PGD(2) receptors is required for LTC(4) production by human eosinophils.

Authors:  Graham A Mackay; Alastair G Stewart
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

5.  Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.

Authors:  M M Teixeira; A G Rossi; M A Giembycz; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.

Authors:  A Tachibana; M Kato; H Kimura; T Fujiu; M Suzuki; A Morikawa
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

7.  Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF.

Authors:  M P Hallsworth; M A Giembycz; P J Barnes; T H Lee
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

8.  Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.

Authors:  A Hatzelmann; H Tenor; C Schudt
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 9.  Single-isomer levalbuterol: a review of the acute data.

Authors:  Richard Nowak
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

Review 10.  Adrenergic regulation of innate immunity: a review.

Authors:  Angela Scanzano; Marco Cosentino
Journal:  Front Pharmacol       Date:  2015-08-13       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.